Studying coagulation in COVID-19 using blood-vessel-on-chip technology.

Recruiting

• Conditions: increased coagulation; 10064477; 10047438

• Registration Number: NL-OMON51031
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 36

Inclusion Criteria

1) Age >18 yr or older
2) Suspected SARS-CoV-2 infection
3) Need for oxygen supplementation
4) CRP-level * 50 mg/L
5) D-dimer level *1.0 mg/L
6) Ability to provide written informed consent

Exclusion Criteria

1) History of venous thromboembolism
2) Use of anticoagulant therapy at inclusion
3) Known hereditary or acquired thrombophilia

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome will be in situ platelet aggregation and coagulation<br /><br>measured using the blood-vessel-on-chip technology.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes include changes in gene expression profiles in the chip, and<br /><br>markers of coagulopathy (e.g. D-dimer) and neutrophil extracellular traps (e.g.<br /><br>citrullinated histone H3). </p><br>